Sanofi begins trial of Kevzara against COVID-19 complicationsSanofi and Regeneron are throwing an already-approved drug at COVID-19, testing Kevzara (sarilumab) in patients hospitalised with severe Share XSanofi begins trial of Kevzara against COVID-19 complicationshttps://pharmaphorum.com/news/sanofi-begins-trial-of-kevzara-against-covid-19-complications/
NICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmaNICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in Share XNICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmahttps://pharmaphorum.com/news/nice-rejects-nhs-funding-sanofi-regenerons-dupixent-in-asthma/
GSK’s Walmsley gets £2.5m pay rise after strong 2019There can’t be many people in the UK who enjoyed a £2.5 million pay rise this year – Share XGSK’s Walmsley gets £2.5m pay rise after strong 2019https://pharmaphorum.com/news/gsks-walmsley-gets-2-5m-pay-rise-after-strong-sales/
Novartis’ Beovu safety woes could cost billions of dollars, says analystThe launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several Share XNovartis’ Beovu safety woes could cost billions of dollars, says analysthttps://pharmaphorum.com/news/novartis-beovu-launch-could-be-hit-by-safety-warning/
Lilly swoops on Dermira to claim Dupixent rivalEli Lilly agreed on Friday to buy dermatology specialist Dermira for $1.1 billion and its lead drug, a Share XLilly swoops on Dermira to claim Dupixent rivalhttps://pharmaphorum.com/news/lilly-swoops-on-dermira-to-claim-dupixent-rival/
Regeneron/Sanofi get EU okay for Dupixent in “asthma of the sinuses”Regeneron and Sanofi’s immunology drug Dupixent has been approved for a third indication in Europe, adding the treatment Share XRegeneron/Sanofi get EU okay for Dupixent in “asthma of the sinuses”https://pharmaphorum.com/news/regeneron-sanofi-get-eu-okay-for-dupixent-in-asthma-of-the-sinuses/
Pfizer’s Xeljanz follow-up abrocitinib gathers momentumPfizer has reported new data with abrocitinib, a follow-up to its JAK inhibitor Xeljanz, which is facing increased Share XPfizer’s Xeljanz follow-up abrocitinib gathers momentumhttps://pharmaphorum.com/news/pfizers-xeljanz-follow-up-abrocitinib-gathers-momentum/
Sanofi’s Dupixent backed for nasal polyps use in EuropeSanofi and Regeneron’s fast-growing immunology drug Dupixent is on course for a third indication in Europe after being Share XSanofi’s Dupixent backed for nasal polyps use in Europehttps://pharmaphorum.com/news/sanofis-dupixent-backed-for-nasal-polyps-use-in-europe/
Novartis backs brolucizumab with new head-to-head Eylea trialNovartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Share XNovartis backs brolucizumab with new head-to-head Eylea trialhttps://pharmaphorum.com/news/novartis-backs-brolucizumab-with-new-head-to-head-eylea-trial/
